|
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study Of RAD001 Adjuvant Therapy In Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-Line Rituximab Chemotherapy
|
This study is being done to see if giving RAD001 can reduce the chance of relapse when it is given to patients with diffuse large B-cell lymphoma that is in complete remission. Rad001 is currently not approved by the FDA for use in this situation therefore, this treatment is considered experimental.
|
Principal Investigator(s):
Tarun Kewalramani, MD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Deborah J. Gannon,
Nancy M. Campbell, RN.
|
|
S0806, A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)
|
The standard treatment for DLBCL is a combination of the drugs rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (called "RCHOP"). In many patients with DLBCL the lymphoma can return (“relapse”) after treatment with RCHOP. Vorinostat is a drug that may be effective in treating DLBCL. This experimental study is being done to see how well the combination of vorinostat and RCHOP can work to reduce the chance of DLBCL returning.
|
Principal Investigator(s):
Tarun Kewalramani, MD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Kathleen (Kai) Sherman.
|